Table 1.
Characteristics | Number | % | |
---|---|---|---|
Age | |||
Median (years) | 36 | ||
Range | 19–77 | ||
Karyotype | |||
Normal | 6 | 19% | |
t(9;22) | 4 | 13% | |
t(v;11q23) | 3 | 10% | |
Complex (≥3 aberrations) | 3 | 10% | |
p16 | 3 | 10% | |
Other | 4 | 13% | |
NA | 8 | 26% | |
Lactic Dehydrogenase (IU/L) | |||
Median | 755 | ||
Range | 145–10,000 | ||
White blood cell count (×109/L) | |||
Median | 3.3 | ||
Range | <0.1 – 121.4 | ||
Treatment Status* | |||
Salvage 1 | 6 | 19% | |
Salvage 2 | 8 | 26% | |
Salvage 3 | 6 | 19% | |
Salvage 4 | 6 | 19% | |
Salvage 5 or more | 5 | 16% | |
ECOG Performance Status† | |||
0 | 8 | 27% | |
1 | 17 | 57% | |
2 | 5 | 17% |
Two patients relapsed following an allogeneic SCT prior to enrollment in the trial
Data available on 30 patients only
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not available;